| scholarly article | Q13442814 |
| P50 | author | Ron C Hoogeveen | Q60644631 |
| Elizabeth Selvin | Q66473921 | ||
| David Aguilar | Q85774641 | ||
| Menglu Liang | Q88385879 | ||
| Christie M. Ballantyne | Q98665268 | ||
| P2093 | author name string | Josef Coresh | |
| Morgan E Grams | |||
| Casey M Rebholz | |||
| John W McEvoy | |||
| P2860 | cites work | Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis | Q24649584 |
| A new equation to estimate glomerular filtration rate | Q24651973 | ||
| Galectins. Structure and function of a large family of animal lectins | Q28246794 | ||
| Galectins: structure, function and therapeutic potential | Q28283659 | ||
| The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators | Q29614947 | ||
| Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium | Q30418185 | ||
| United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease | Q30975799 | ||
| Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury | Q33873592 | ||
| Identification of incident CKD stage 3 in research studies | Q33954425 | ||
| Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans | Q34122713 | ||
| Association of 1,5-anhydroglucitol with diabetes and microvascular conditions | Q34433155 | ||
| Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction | Q34528187 | ||
| Galectin-3: a novel mediator of heart failure development and progression | Q34995162 | ||
| Therapy of experimental NASH and fibrosis with galectin inhibitors | Q35075568 | ||
| Estimating glomerular filtration rate from serum creatinine and cystatin C. | Q35429171 | ||
| Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values | Q35574977 | ||
| Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. | Q35798551 | ||
| Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria | Q35889693 | ||
| Kidney Failure and ESRD in the Atherosclerosis Risk in Communities (ARIC) Study: Comparing Ascertainment of Treated and Untreated Kidney Failure in a Cohort Study | Q35893524 | ||
| Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies | Q36003071 | ||
| Galectin-3 Blockade Reduces Renal Fibrosis in Two Normotensive Experimental Models of Renal Damage | Q36187612 | ||
| Dietary Acid Load and Incident Chronic Kidney Disease: Results from the ARIC Study | Q36522360 | ||
| Recalibration of blood analytes over 25 years in the atherosclerosis risk in communities study: impact of recalibration on chronic kidney disease prevalence and incidence. | Q36661937 | ||
| Analogs of tetrahydroisoquinoline natural products that inhibit cell migration and target galectin-3 outside of its carbohydrate-binding site | Q36861463 | ||
| Relationship of the American Heart Association's Impact Goals (Life's Simple 7) With Risk of Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Cohort Study | Q36877258 | ||
| Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites | Q36956715 | ||
| Elevated galectin-3 precedes the development of CKD | Q37119904 | ||
| Galectin-3 in cardiac remodeling and heart failure | Q37738648 | ||
| Aldosterone mediates cardiac fibrosis in the setting of hypertension. | Q38107897 | ||
| GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration | Q38274063 | ||
| Galectin-3 Serum Levels Are Independently Associated With Microalbuminuria in Chronic Heart Failure Outpatients | Q38309028 | ||
| Galectin-3 in Renal Pathology: More Than Just an Innocent Bystander | Q38831547 | ||
| DASH (Dietary Approaches to Stop Hypertension) Diet and Risk of Subsequent Kidney Disease | Q39494977 | ||
| Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors | Q39605793 | ||
| Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy | Q41695164 | ||
| The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. | Q41744993 | ||
| GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death | Q42324031 | ||
| Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate | Q43973123 | ||
| Galectin-3 and Soluble ST2 and Kidney Function Decline in Older Adults: The Cardiovascular Health Study (CHS). | Q46506580 | ||
| Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. | Q48546353 | ||
| Short-term, within-person variability in clinical chemistry test results. Experience from the Atherosclerosis Risk in Communities Study. | Q51595380 | ||
| First certified reference material for cystatin C in human serum ERM-DA471/IFCC. | Q51746125 | ||
| Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis? | Q53233664 | ||
| Toward using confidence intervals to compare correlations. | Q54658653 | ||
| Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis | Q61187743 | ||
| Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments | Q62084084 | ||
| Galectin-3 Is an Amplifier of Inflammation in Atherosclerotic Plaque Progression Through Macrophage Activation And Monocyte Chemoattraction | Q62657999 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 252-259 | |
| P577 | publication date | 2017-08-30 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease | |
| P478 | volume | 93 |
| Q97644527 | Associations Between Plasma Immunomodulatory and Inflammatory Mediators With VACS Index Scores Among Older HIV-Infected Adults on Antiretroviral Therapy |
| Q88983378 | GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD |
| Q90169765 | Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs |
| Q89429779 | Galectin-1 is a new fibrosis protein in type 1 and type 2 diabetes |
| Q50126684 | Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus |
| Q89486528 | High-sensitivity Troponin I Predicts Galectin-3 in Chronic Kidney Disease Patients |
| Q90677157 | Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes |
Search more.